Immunopathogenesis and therapy of cutaneous T cell lymphoma.
Authors:
- Ellen J KimEKEllen J Kim
- Stephen HessSHStephen Hess
- Stephen K RichardsonSRStephen K Richardson
- Sara NewtonSNSara Newton
- Louise C ShoweLSLouise C Showe
- Bernice M BenoitBBBernice M Benoit
- Ravi UbrianiRURavi Ubriani
- Carmela C VittorioCVCarmela C Vittorio
- Jacqueline M Junkins-HopkinsJJJacqueline M Junkins-Hopkins
- Maria WysockaMWMaria Wysocka
- Alain H RookARAlain H Rook
- 1 April 2005
- journal article
- review article
- Vol. 115 (4) , 798-812
Abstract
Cutaneous T cell lymphomas (CTCLs) are a heterogenous group of lymphoproliferative disorders caused by clonally derived, skin-invasive T cells. Mycosis fungoides (MF) and Sezary syndrome (SS) are the most common types of CTCLs and are characterized by malignant CD4(+)/CLA(+)/CCR4(+) T cells that also lack the usual T cell surface markers CD7 and/or CD26. As MF/SS advances, the clonal dominance of the malignant cells results in the expression of predominantly Th2 cytokines, progressive immune dysregulation in patients, and further tumor cell growth. This review summarizes recent insights into the pathogenesis and immunobiology of MF/SS and how these have shaped current therapeutic approaches, in particular the growing emphasis on enhancement of host antitumor immune responses as the key to successful therapy.Keywords
This publication has 100 references indexed in Scilit:
- Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-cell lymphoma: clinical synergism and possible immunologic mechanismsJournal of the American Academy of Dermatology, 2004
- Extracorporeal Photopheresis and Multimodality Immunomodulatory Therapy in the Treatment of Cutaneous T-Cell LymphomaJournal of Cutaneous Medicine and Surgery, 2003
- Novel multimodality biologic response modifier therapy, including bexarotene and long-wave ultraviolet A for a patient with refractory stage IVa cutaneous T-cell lymphomaJournal of the American Academy of Dermatology, 2002
- Infrequent Fas Mutations but No Bax or p53 Mutations in Early Mycosis Fungoides: A Possible Mechanism for the Accumulation of Malignant T Lymphocytes in the SkinJournal of Investigative Dermatology, 2002
- The T-Cell Chemokine Receptor CXCR3 Is Expressed Highly in Low-Grade Mycosis FungoidesAmerican Journal of Clinical Pathology, 2001
- Twenty-year trends in the reported incidence of mycosis fungoides and associated mortality.American Journal of Public Health, 1999
- Treatment of mycosis fungoides with photochemotherapy (PUVA): Long-term follow-upJournal of the American Academy of Dermatology, 1995
- Treatment of cutaneous T cell lymphoma with a combination of low-dose interferon alfa-2b and retinoidsJournal of the American Academy of Dermatology, 1991
- Leu-8/CD7 antigen expression by CD3+ T cells: Comparative analysis of skin and blood in mycosis fungoides/Sézary syndrome relative to normal blood valuesJournal of the American Academy of Dermatology, 1990
- An unusual and fatal case of disseminated cutaneous herpes simplexJournal of the American Academy of Dermatology, 1981